News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Peregrine Announces Product Development Agreement With Medipharm Biotech for Tumor Necrosis Therapy -TNT- in the People`s Republic of China (Business Wire) ...Collateral targeting agents are designed to bind to elements of tumors that are common to all solid tumors or are the product of tumor growth....... is currently in a multi-center Phase II clinical study for the treatment of brain cancer and in four Phase I clinical trials for the treatment of colorectal,... - Sep 06 8:13 AM ET

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557